Literature DB >> 25245243

Gynaecological cancer: HPV vaccine: is age just a number?

Louise Stone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25245243     DOI： 10.1038/nrurol.2014.268

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  2 in total

1.  Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.

Authors:  S Rachel Skinner; Anne Szarewski; Barbara Romanowski; Suzanne M Garland; Eduardo Lazcano-Ponce; Jorge Salmerón; M Rowena Del Rosario-Raymundo; René H M Verheijen; Swee Chong Quek; Daniel P da Silva; Henry Kitchener; Kah Leng Fong; Céline Bouchard; Deborah M Money; Arunachalam Ilancheran; Margaret E Cruickshank; Myron J Levin; Archana Chatterjee; Jack T Stapleton; Mark Martens; Wim Quint; Marie-Pierre David; Dorothée Meric; Karin Hardt; Dominique Descamps; Brecht Geeraerts; Frank Struyf; Gary Dubin
Journal:  Lancet       Date:  2014-09-01       Impact factor: 79.321

2.  Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland.

Authors:  K G J Pollock; K Kavanagh; A Potts; J Love; K Cuschieri; H Cubie; C Robertson; M Cruickshank; T J Palmer; S Nicoll; M Donaghy
Journal:  Br J Cancer       Date:  2014-09-02       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.